169 related articles for article (PubMed ID: 16636339)
1. Irinogenetics: what is the right star?
Innocenti F; Vokes EE; Ratain MJ
J Clin Oncol; 2006 May; 24(15):2221-4. PubMed ID: 16636339
[No Abstract] [Full Text] [Related]
2. Insights, challenges, and future directions in irinogenetics.
Kim TW; Innocenti F
Ther Drug Monit; 2007 Jun; 29(3):265-70. PubMed ID: 17529881
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Inoue K; Sonobe M; Kawamura Y; Etoh T; Takagi M; Matsumura T; Kikuyama M; Kimura M; Minami S; Utsuki H; Yamazaki T; Suzuki T; Tsuji D; Hayashi H; Itoh K
Tohoku J Exp Med; 2013 Feb; 229(2):107-14. PubMed ID: 23303296
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Nagar S; Blanchard RL
Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
[TBL] [Abstract][Full Text] [Related]
5. Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Takano M; Kato M; Yoshikawa T; Goto T; Furuya K; Kikuchi Y
Int J Clin Oncol; 2010 Apr; 15(2):224-5. PubMed ID: 20179984
[No Abstract] [Full Text] [Related]
6. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
[TBL] [Abstract][Full Text] [Related]
7. NF-kappa B activation in topoisomerase I inhibitor-induced apoptotic cell death in human non-small cell lung cancer.
Tabata M; Ganapathi R
Ann N Y Acad Sci; 2000; 922():343-4. PubMed ID: 11193918
[No Abstract] [Full Text] [Related]
8. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Akiyama Y; Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Araki K; Ichikawa W; Miya T; Narabayashi M; Kawara K; Sugiyama M; Hirose T; Ando Y; Sasaki Y
Ann Oncol; 2008 Dec; 19(12):2089-90. PubMed ID: 18953066
[No Abstract] [Full Text] [Related]
9. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Ando M; Hasegawa Y; Ando Y
Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624
[TBL] [Abstract][Full Text] [Related]
10. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan in small-cell lung cancer.
Ando Y; Figg WD
N Engl J Med; 2002 May; 346(18):1414-5; author reply 1414-5. PubMed ID: 11986422
[No Abstract] [Full Text] [Related]
13. [Chemotherapy of solid tumors: pharmacologic activity or effectiveness?].
Longo F; Mansueto G
Tumori; 1999; 85(6):A26-33. PubMed ID: 10774584
[No Abstract] [Full Text] [Related]
14. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Zhao M; Gjerset RA
PLoS One; 2015; 10(8):e0134929. PubMed ID: 26248194
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
[TBL] [Abstract][Full Text] [Related]
17. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Sai K; Saito Y; Sakamoto H; Shirao K; Kurose K; Saeki M; Ozawa S; Kaniwa N; Hirohashi S; Saijo N; Sawada J; Yoshida T
Cancer Lett; 2008 Mar; 261(2):165-71. PubMed ID: 18082937
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.
Ando M; Ando Y; Sekido Y; Ando M; Shimokata K; Hasegawa Y
Jpn J Cancer Res; 2002 May; 93(5):591-7. PubMed ID: 12036456
[TBL] [Abstract][Full Text] [Related]
19. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
[TBL] [Abstract][Full Text] [Related]
20. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
